High Potency API Contract Manufacturing Market to expand at a 7% value CAGR by 2032
A recently published study by FMI expects the global high potency API contract manufacturing market to augment at a 7% CAGR from 2022 to 2032. By the end of the said assessment period, a valuation of US$ 8 Billion is expected for the market.Rising breakthroughs in high potency API (HPAPI) manufacturing technologies,...
New York United States United Arab Emirates Asia Pacific Cordenpharma International Piramal Pharm Solutions
Source: pharmiweb.com